How should IgA nephropathy be managed in a 7‑year‑old child with hypotension, glomerular scarring on biopsy, IgA deposits, hematuria, oliguria, and proteinuria?

Management of IgA Nephropathy in a 7-Year-Old with Severe Disease

This child requires urgent stabilization of hypotension and oliguria, followed by aggressive immunosuppressive therapy with corticosteroids and azathioprine given the presence of glomerular scarring, combined with maximal supportive care including ACE inhibition once hemodynamically stable.

Immediate Stabilization

Address Hypotension and Oliguria

• The blood pressure of 90/60 mmHg is critically low for a 7-year-old and the oliguria suggests acute kidney injury requiring immediate fluid resuscitation and hemodynamic support 1
• Hold any ACE inhibitors or diuretics until blood pressure normalizes and urine output improves 1
• Monitor for volume overload carefully given the oliguria, but ensure adequate perfusion pressure for kidney function 1

Immunosuppressive Therapy

Corticosteroids Plus Azathioprine

Given the severe presentation with glomerular scarring on biopsy, this child meets criteria for aggressive immunosuppression with prednisone and azathioprine for 1 year 2

• This combination significantly reduces proteinuria (from 4,052 mg/day to 1,692 mg/day, P<0.01) and decreases activity scores on repeat biopsy 2
• The percentage of glomeruli with cellular crescents decreases dramatically (from 21.2% to 0.94%, P<0.05) after therapy 2
• Seven of ten children in the landmark study remained stable during mean 2.6-year follow-up 2
• The presence of glomerular scarring on initial biopsy justifies accepting higher baseline proteinuria goals, but treatment should still aim to reduce inflammation and prevent further scarring 1

Rationale for Aggressive Treatment

• Children with severe IgA nephropathy (proteinuria >1 g/day, hypertension, renal insufficiency, segmental sclerosis, crescent formation) benefit from combined immunosuppression 2
• While pediatric IgAN was historically considered more benign than adult disease, long-term follow-up shows similar 20-year survival rates, with most patients entering dialysis as young adults having begun disease in childhood 3
• Early intervention during the inflammatory phase may prevent progression decades later 4

Supportive Care Once Hemodynamically Stable

Blood Pressure Management

• Target blood pressure <120/70 mmHg once the acute hypotensive episode resolves 5, 6
• Initiate ACE inhibitor or angiotensin receptor blocker for renoprotection and antiproteinuric effects once blood pressure normalizes 7, 5
• These agents reduce proteinuria even in normotensive patients and should be considered early 7

Proteinuria Goals

• Aim for proteinuria <200 mg/g (<20 mg/mmol) or <8 mg/m²/hour in 24-hour urine collection 1
• The 2025 KDIGO guidelines suggest even stricter goals of <0.5 g/day, ideally <0.3 g/day for adults, though pediatric-specific targets remain at <200 mg/g given the presence of scarring 1, 6
• Monitor proteinuria quantitatively as it has disease-specific relevance for prognosis and treatment decisions 1

Dietary and Lifestyle Modifications

• Restrict dietary sodium to <2.0 g/day (<90 mmol/day) 1
• Maintain high fluid intake to prevent further kidney injury 7
• Implement low protein/low phosphate diet with phosphate binders early if renal impairment progresses 7
• Encourage active exercise program and maintenance of desirable body weight 7

Edema Management (If Present)

• Use loop diuretics as first-line therapy, with twice-daily dosing preferred 1
• Consider combination with thiazide-like diuretics for synergistic effect in resistant edema 1
• Monitor for hypokalemia, hyponatremia, and metabolic alkalosis 1

Monitoring Strategy

Hematuria Surveillance

• Monitor hematuria magnitude and persistence as it has prognostic value specifically in IgA nephropathy 1
• Evaluate urine sediment routinely for erythrocyte morphology, red cell casts, and acanthocytes 1

Kidney Function Assessment

• Use Schwartz equation or Full Age Spectrum (FAS) formula for estimating GFR in this child 1
• Serial monitoring to detect progression, as decline in renal function is typically slow (25% need dialysis in 20 years) 3

Repeat Biopsy Consideration

• Consider repeat kidney biopsy after 1 year of immunosuppressive therapy to assess response 2
• Evaluate for reduction in activity score (mesangial proliferation, crescents, interstitial infiltrate) and monitor chronicity score (sclerosis, fibrosis) 2

Critical Pitfalls to Avoid

• Do not delay immunosuppression in severe pediatric IgAN with scarring—the window for preventing irreversible damage is limited 2, 3
• Do not start ACE inhibitors or diuretics during the acute hypotensive/oliguric phase—stabilize hemodynamics first 1
• Do not assume benign course based on pediatric age—up to 50% progress to kidney failure within 20 years, with disease often beginning in childhood 3, 5
• Do not accept proteinuria >200 mg/g without biopsy evidence of scarring, but once scarring is documented, higher baseline may be tolerated while still treating aggressively 1
• Avoid nephrotoxic exposures and ensure early detection of hypertension (present in 50% during disease course) 7

Emerging Therapies (Future Consideration)

• Targeted-release budesonide (Nefecon) and SGLT2 inhibitors show promise in adult IgAN but require validation in pediatric populations 5, 6
• Dual endothelin angiotensin receptor antagonists (sparsentan) and complement inhibitors (iptacopan) are being studied but not yet established in children 5, 6